NuWays set EUR 21.50 target for Eckert & Ziegler stock

Published on 10/22/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter sales are projected at EUR 78.80 million. Eckert & Ziegler stock costs EUR 13.29 on October 22, 2026, 0.23 percent below Xetra close.

Targets and quarterly evidence

NuWays set a 12-month target of EUR 21.50 on October 13, 2026.
The third-quarter estimate puts adjusted EBIT at EUR 18.20 million, up 18.20 percent year on year.
Eckert & Ziegler stock traded at EUR 13.29 at 11:59 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.23 percent below the Xetra close of October 21, 2026.

Makrofoto von pharmazeutischen Glasfläschchen mit türkis leuchtender Isotopenlösung — Eckert & Ziegler DE0005659700 Medizintechnik: Extreme Makroaufnahme kleiner Glasfläschchen mit leuchtend blau-grüner radioaktiver Isotopenlösung, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) was trading at EUR 13.29 at Lang & Schwarz on October 22, 2026, 0.23 percent below the Xetra close of October 21, 2026. NuWays set a 12-month target of EUR 21.50 for the company on October 13, 2026, according to EQS News.

NuWays sees third-quarter recovery

The research projects third-quarter 2026 revenue of EUR 78.80 million, a 4.60 percent increase from the prior-year period. Adjusted EBIT is projected at EUR 18.20 million, up 18.20 percent year on year, with an adjusted EBIT margin of 23.10 percent, according to TradingView. The estimate places Medical revenue at EUR 40.00 million and Isotope Products revenue at EUR 39.00 million.

Eckert & Ziegler operates in medical, scientific and measurement applications, with Medical and Isotope Products as its two operating segments, according to Eckert & Ziegler. Its investor page lists EUR 312.00 million of revenue and EUR 77.70 million of adjusted EBIT for fiscal year 2025.

What will the report test?

The key test is whether the projected EBIT improvement arrives alongside revenue growth. NuWays expects Isotope Products adjusted EBIT to recover 23.00 percent quarter on quarter to EUR 8.00 million, while Medical adjusted EBIT is projected at EUR 11.00 million, up 43.00 percent year on year. The estimate includes no license revenue in the third quarter, leaving a potential additional contribution of at least EUR 3.00 million in the fourth quarter.

Two reporting dates ahead

EQS News lists November 12, 2026 as the publication date for the third-quarter financial report and March 24, 2027 for the annual financial report.

Price stays below target

The NuWays target is EUR 8.21 above the Lang & Schwarz quote, but the target remains an analyst estimate rather than a company forecast. Eckert & Ziegler was trading at EUR 13.29 at Lang & Schwarz on October 22, 2026 at 11:59 a.m. CEST, 0.23 percent below the Xetra close of October 21, 2026 at EUR 13.32. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.